# RAI1 Target Configuration for PhaseLab CRISPRa
# Smith-Magenis Syndrome - validated on IBM Quantum hardware

gene_symbol: "RAI1"
genome_build: "GRCh38"

# Gene information
gene_id: "ENSG00000108557"
refseq_id: "NC_000017.11"
uniprot_id: "Q7Z5J4"

promoter:
  chrom: "chr17"
  start: 17680458        # TSS - 1000 bp
  end:   17681958        # TSS + 500 bp
  tss:   17681458        # GRCh38 RAI1 TSS (Ensembl)

crispr:
  system: "SpCas9"
  pam: "NGG"
  window:
    # CRISPRa window relative to TSS
    start_offset: -400
    end_offset: -50

filters:
  gc_min: 0.40
  gc_max: 0.70
  max_homopolymer: 4
  min_complexity: 0.5

scoring:
  use_thermodynamics: true
  use_offtarget: true
  use_chromatin: true
  use_coherence: true
  coherence_threshold: 0.135   # e^-2

chromatin:
  source: "ENCODE"
  tissue: "mixed"
  cell_type: "unspecified"
  tracks:
    - "encode_dnase_general"

notes:
  disease: "Smith-Magenis Syndrome (SMS)"
  omim: "182290"
  mode: "haploinsufficiency"
  therapeutic_goal: "Boost remaining allele by 20-60% to restore circadian and transcriptional function"

  # PhaseLab validation
  hardware_validation:
    backend: "ibm_torino"
    job_id: "d4suvd7t3pms7399mq8g"
    date: "2025-12-10"
    top_guide: "TACAGGAGCTTCCAGCGTCA"
    coherence_R: 0.839
    mit_score: 83
    cfd_score: 93

  references:
    - title: "rAAV-CRISPRa therapy for Smith-Magenis Syndrome"
      journal: "PMC"
      year: 2022
      pmcid: "PMC9762195"
